Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

GastroEsophageal Cancer × Lapatinib × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7 Neoplasms 4 Neoplasm Metastasis 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Pancreatic Neoplasms 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Gallbladder Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Prostatic Neoplasms 1 Oesophagogastric Cancer 1 Lung Neoplasms 1 HER2 Positive Esophagogastric Cancer 1 Gastrointestinal Neoplasms 1 GastroEsophageal Cancer 1 Esophageal Squamous Cell Carcinoma 1 Dysgerminoma 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Bile Duct Neoplasms 1

Interventions

Surveys and Questionnaires 2 Lapatinib 1 Immune Checkpoint Inhibitors 1 Exercise 1 Diet Therapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01145404 2014-07-02

GastroLap

National Center for Tumor Diseases, Heidelberg

Phase 2 Terminated

Gastrointestinal

GastroEsophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡